Benzinga · Feb 26, 2026
Why Is CRISPR Therapeutics Stock Surging Thursday?
CRSP shares jump on earnings report, strong pipeline for gene therapy. Revenue grows with increased patient treatment and analyst confidence.
CR
NASDAQ · CRSP
CRISPR Therapeutics AG
Healthcare · Biotechnology
$56.98
Down-$0.25 (-0.44%)
Updated Sep 1, 2026, 7:28 PM
SID Score
5.5/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 5.08B
- P/E ratio
- -10.81
- Dividend yield
- 0.00%
- 52-week range
- $44.12 – $78.48
- Volume
- 1.39M
- Avg. volume
- 2.56M
Price performance
CRSP price history
1M range · 0 trading sessions · Daily adjusted prices
CRSP does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest CRSP news
The latest Smart Investors Daily articles mentioning CRSP.
Stock researchCompany · Overview
CRSP research
Overview
Company profile and research snapshot.
Company profile
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $66.33
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 31, 2026 | Citizens | Market Outperform | — |
| Aug 31, 2026 | Needham | Buy | — |
| Aug 25, 2026 | Citizens | Market Outperform | — |
| Aug 4, 2026 | Citigroup | Buy | — |
| Jul 8, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Feb 18, 2026
Crispr Therapeutics: Very High Risk But Even Higher Potential Reward
CRISPR Therapeutics (CRSP) rated Buy: CASGEVY launch drives $5.8B peak sales potential and 73% upside, backed by strong cash.
SeekingAlpha · Feb 18, 2026
CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
SeekingAlpha · Feb 18, 2026
Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade)
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
